Therapies aiming to induce systemic neutrophil expansion (e.g., G-CSF) in combination with agents that promote the generation of anti-tumor neutrophils (e.g., TGFβ targeting) might act synergistically, and induce greater cytotoxicity in the tumor. Here, CSF3 is linked to neoplasm.